Chronic hypoparathyroidism (HypoPT) is a rare disease associated with a variety of symptoms and diminished health-related quality of life (HRQoL). This study aimed to characterise and quantify the symptom burden, HRQoL, and overall disease impact in patients receiving recombinant human parathyroid hormone (rhPTH1-84, Natpar®) for inadequately controlled HypoPT and in symptomatic patients receiving standard therapy (ST; calcium and/or vitamin D supplements).
Kristina Chen, Nandini Hadker, Irana Abibova, Lachlan Hanbury-Brown, Montserrat Vera-Llonch, Bart Clarke
ENDO Meeting, March 2018
ECE Meeting, May 2018
AACE Meeting, May 2018